A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia
Sponsor: Otsuka Pharmaceutical Co., Ltd.
A PHASE2/PHASE3 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Otsuka Pharmaceutical Co., Ltd. and has accumulated 6 data snapshots since 2011. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Nov 2019 [monthly]
Completed PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .